These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 28662545)
21. Molecular phenotype and bleeding risks of an inherited platelet disorder in a family with a RUNX1 frameshift mutation. Badin MS; Iyer JK; Chong M; Graf L; Rivard GE; Waye JS; Paterson AD; Pare G; Hayward CPM Haemophilia; 2017 May; 23(3):e204-e213. PubMed ID: 28181366 [TBL] [Abstract][Full Text] [Related]
22. Deficiency of (33P)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Cattaneo M; Lombardi R; Zighetti ML; Gachet C; Ohlmann P; Cazenave JP; Mannucci PM Thromb Haemost; 1997 May; 77(5):986-90. PubMed ID: 9184415 [TBL] [Abstract][Full Text] [Related]
23. Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha granules. Gerrard JM; Phillips DR; Rao GH; Plow EF; Walz DA; Ross R; Harker LA; White JG J Clin Invest; 1980 Jul; 66(1):102-9. PubMed ID: 6156948 [TBL] [Abstract][Full Text] [Related]
24. Grey platelet syndrome: studies on platelet alpha-granules, lysosomes and defective response to thrombin. Srivastava PC; Powling MJ; Nokes TJ; Patrick AD; Dawes J; Hardisty RM Br J Haematol; 1987 Apr; 65(4):441-6. PubMed ID: 3580300 [TBL] [Abstract][Full Text] [Related]
25. A major role of ADP in thromboxane transfer experiments: studies in patients with platelet secretion defects. Rao AK; Willis J; Holmsen H J Lab Clin Med; 1984 Jul; 104(1):116-26. PubMed ID: 6429260 [TBL] [Abstract][Full Text] [Related]
26. Platelet-activating factor is a weak platelet agonist: evidence from normal human platelets and platelets with congenital secretion defects. Rao AK; Willis J; Hassell B; Dangelmaier C; Holmsen H; Smith JB Am J Hematol; 1984 Aug; 17(2):153-65. PubMed ID: 6431801 [TBL] [Abstract][Full Text] [Related]
27. Inhibitors of Na+/H+ exchange block stimulus-provoked arachidonic acid release in human platelets. Selective effects on platelet activation by epinephrine, ADP, and lower concentrations of thrombin. Sweatt JD; Johnson SL; Cragoe EJ; Limbird LE J Biol Chem; 1985 Oct; 260(24):12910-9. PubMed ID: 2997148 [TBL] [Abstract][Full Text] [Related]
29. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Cattaneo M; Lecchi A; Lombardi R; Gachet C; Zighetti ML Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):E101-6. PubMed ID: 11073862 [TBL] [Abstract][Full Text] [Related]
30. Platelet metabolism and activation. Holmsen H Semin Hematol; 1985 Jul; 22(3):219-40. PubMed ID: 2994234 [TBL] [Abstract][Full Text] [Related]
31. Mechanism of platelet factor 4 (PF4) deficiency with RUNX1 haplodeficiency: RUNX1 is a transcriptional regulator of PF4. Aneja K; Jalagadugula G; Mao G; Singh A; Rao AK J Thromb Haemost; 2011 Feb; 9(2):383-91. PubMed ID: 21129147 [TBL] [Abstract][Full Text] [Related]
32. Content and thrombin-induced release of acid hydrolases in gel-filtered platelets from patients with storage pool disease. Holmsen H; Setkowsky CA; Lages B; Day HJ; Weiss HJ; Scrutton MC Blood; 1975 Jul; 46(1):131-42. PubMed ID: 1131424 [TBL] [Abstract][Full Text] [Related]
33. Effect of physiologic shear stresses and calcium on agonist-induced platelet aggregation, secretion, and thromboxane A2 formation. Viisoreanu D; Gear A Thromb Res; 2007; 120(6):885-92. PubMed ID: 17306868 [TBL] [Abstract][Full Text] [Related]
34. Platelet dysfunction caused by a novel thromboxane A Bugert P; Fischer L; Althaus K; Knöfler R; Bakchoul T Platelets; 2020; 31(2):276-279. PubMed ID: 31389738 [TBL] [Abstract][Full Text] [Related]
35. Quantification of energy consumption in platelets during thrombin-induced aggregation and secretion. Tight coupling between platelet responses and the increment in energy consumption. Verhoeven AJ; Mommersteeg ME; Akkerman JW Biochem J; 1984 Aug; 221(3):777-87. PubMed ID: 6236799 [TBL] [Abstract][Full Text] [Related]
36. Thrombin pretreatment of human platelets impairs thromboxane A2 synthesis from endogenous precursors in the presence of normal cyclooxygenase activity. Reimers HJ; Scharf RE; Baker RK Blood; 1984 Apr; 63(4):858-65. PubMed ID: 6231068 [TBL] [Abstract][Full Text] [Related]
37. Impaired platelet response to thromboxane-A2 and defective calcium mobilization in a patient with a bleeding disorder. Lages B; Malmsten C; Weiss HJ; Samuelsson B Blood; 1981 Mar; 57(3):545-52. PubMed ID: 7459434 [TBL] [Abstract][Full Text] [Related]
38. Evidence for a role for Galphai1 in mediating weak agonist-induced platelet aggregation in human platelets: reduced Galphai1 expression and defective Gi signaling in the platelets of a patient with a chronic bleeding disorder. Patel YM; Patel K; Rahman S; Smith MP; Spooner G; Sumathipala R; Mitchell M; Flynn G; Aitken A; Savidge G Blood; 2003 Jun; 101(12):4828-35. PubMed ID: 12609843 [TBL] [Abstract][Full Text] [Related]
39. Effects of antimycin A and 2-deoxyglucose on secretion in human platelets. Differential inhibition of the secretion of acid hydrolases and adenine nucleotides. Holmsen H; Robkin L; Day HJ Biochem J; 1979 Aug; 182(2):413-9. PubMed ID: 508292 [TBL] [Abstract][Full Text] [Related]